EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry

Derralynn A Hughes iD, Gere Sunder-Plassmann, Ana Jovanovic, Eva Brand, Michael L West, Daniel G Bichet, Antonio Pisani, Albina Nowak, Roser Torra, Aneal Khan, Olga Azevedo, Anna Lehman und 5 weitere

Journal of Inherited Metabolic Disease · 2025-01 · 48 (1)

DOI: 10.1002/jimd.12771 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 19.07.2024. Verfasst von Derralynn A Hughes und 16 weiteren Autor:innen. Beteiligte Einrichtung: Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK. Hauptthemen laut MEDLINE: Fabry Disease, 1-Deoxynojirimycin. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amicus Therapeutics, Inc., Takeda Pharmaceutical Company, Boston Scientific Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabry disease is a progressive, X‐linked lysosomal disorder caused by reduced or absent α‐galactosidase A activity due to GLA variants. The effects of migalastat were examined in a cohort of 125 Fabry patients with migalastat‐amenable GLA variants in the followME Pathfinders registry (EUPAS20599), an ongoing, prospective, patient‐focused registry evaluating outcomes for current Fabry disease treatments. We report annualised estimated glomerular filtration rate (eGFR) and Fabry‐associated clinical events (FACEs) in a cohort of patients who had received ≥3 years of migalastat treatment in a real‐world setting. As of August 2022, 125 patients (60% male) had a mean migalastat exposure of 3.9 years. At enrolment, median age was 58 years (males, 57; females, 60) with a mean eGFR of 83.7 mL/min/1.73 m 2 ( n = 122; males, 83.7; females, 83.8) and a median left ventricular mass index of 115.1 g/m 2 ( n = 61; males, 131.2; females, 98.0). Mean (95% confidence interval) eGFR annualised rate of change in the overall cohort ( n = 116) was −0.9 (−10.8, 9.9) mL/min/1.73 m 2 /year with a similar rate of change observed across patients with varying levels of kidney function at enrolment. Despite population age and baseline morbidity, 80% of patients did not experience a FACE during the mean 3.9 years of migalastat exposure. The incidence of renal, cardiac, and cerebrovascular events was 2.0, 83.2, and 4.1 events per 1000 patient‐years, respectively. These data support a role of migalastat in preserving renal function and multisystem effectiveness during ≥3 years of migalastat treatment in this real‐world Fabry population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry Disease1-DeoxynojirimycinHumansMaleFemaleMiddle AgedRegistriesGlomerular Filtration RateAgedAdultalpha-GalactosidaseTreatment OutcomeKidneyProspective StudiesCohort Studies

Stichwörter der Autor:innen

Fabry diseasemigalastatreal world evidence

Substanzen

migalastat1-Deoxynojirimycinalpha-Galactosidase

Autor:innen und Institutionen

  • Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK.
  • Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Northern Care Alliance NHS Foundation Trust, Salford, UK.
  • Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, Interdisciplinary Fabry Center Münster, University Hospital Münster, Münster, Germany.
  • Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Department of Medicine, Hôpital du Sacré-Coeur, University of Montréal, Montréal, Quebec, Canada.

ORCID-Profile: Derralynn A Hughes

Förderung

  • Amicus Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Boston Scientific Corporation
  • Amicus Therapeutics

Zitieren

APA

Hughes, D. A., Sunder-Plassmann, G., Jovanovic, A., Brand, E., West, M. L., Bichet, D. G., Pisani, A., Nowak, A., Torra, R., Khan, A., Azevedo, O., Lehman, A., Linhart, A., Rutecki, J., Giuliano, J. D., Krusinska, E., & Nordbeck, P. (2025). Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry. Journal of Inherited Metabolic Disease, 48(1). https://doi.org/10.1002/jimd.12771

Vancouver

Hughes DA, Sunder-Plassmann G, Jovanovic A, Brand E, West ML, Bichet DG, et al. Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry. Journal of Inherited Metabolic Disease. 2025;48(1). doi:10.1002/jimd.12771

BibTeX
@article{Hughes2025,
  author = {Hughes, Derralynn A and Sunder-Plassmann, Gere and Jovanovic, Ana and Brand, Eva and West, Michael L and Bichet, Daniel G and Pisani, Antonio and Nowak, Albina and Torra, Roser and Khan, Aneal and Azevedo, Olga and Lehman, Anna and Linhart, Aleš and Rutecki, Jasmine and Giuliano, Joseph D and Krusinska, Eva and Nordbeck, Peter},
  title = {Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {1},
  doi = {10.1002/jimd.12771}
}
Kostenlos starten →